An observational study in Spinal Tumors and Surgical Treatment, sponsored by Luzerner Kantonsspital. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Luzerner Kantonsspital · Observational
The Swiss Spinal Tumor Registry is a prospective REDCap-based registry, collecting data of surgically treated patients with primary and metastatic tumors of the spine.
Tumors of the vertebral column consist of primary spinal tumors and malignancies metastasizing to the spine. While primary spine tumors represent a rare condition, metastases to the spine have gradually increased over past decades because of increases in aging population and continued advances in cancer therapy with improved survival times across multiple cancer subtypes. Metastases to the vertebral column are found in up to 70% of cancer patients, with 10% of patients demonstrating epidural spinal cord compression. Therefore, many cancer patients may face spinal surgical intervention at some point of their chronic illness. Numerous surgical treatment options are currently available, ranging from simple cement augmentation over decompression of neural elements to extended instrumentation or reconstruction of the spine, including hybrid procedures that combine these techniques. However, precise surgical treatment guidelines do not exist, likely due to the absence of robust, long-term clinical outcomes data in these patients, and the overall heterogeneous nature of spinal tumors. The primary goal of Swiss-STR is to inform on the effectiveness of current practice in spinal oncology and its impact on patient outcomes. Furthermore, it will help to better categorize the different clinical presentations of spinal tumors, thereby facilitating treatment recommendations, assessing the socio-economic burden of this condition to the healthcare system, and improving the quality of care. In cases of rare tumors, multicenter data pooling will fill significant data gaps, allowing a better understanding of these entities. Finally, the approach is to first build and implement a high-quality registry with efficient electronic data capture strategies across hospital sites in Switzerland, with the potential to later expand internationally, providing opportunities for future international scientific collaboration to push the envelope in cancer research further.
105 studies on the registry are indexed under Spinal Cord Neoplasms; 27 are open to participants now.
This study's planned enrollment of 250 is above the median of 150 across 31 observational studies indexed under Spinal Cord Neoplasms.
Browse Spinal Cord Neoplasms studies →Luzerner Kantonsspital is the lead sponsor of 62 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients suffering from primary or metastatic spinal tumors, undergoing surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary or metastatic spinal tumors undergoing surgical treatment
Functional Outcome as assessed by Karnofsky Performance Status Scale
Rating in 10% steps * 100 Normal no complaints; no evidence of disease. * 90 Able to carry on normal activity; minor signs or symptoms of disease. * 80 Normal activity with effort; some signs or symptoms of disease. * 70 Cares for self; unable to carry on normal activity or to do active work. * 60 Requires occasional assistance, but is able to care for most of his personal needs. * 50 Requires considerable assistance and frequent medical care. * 40 Disabled; requires special care and assistance. * 30 Severely disabled; hospital admission is indicated although death is not imminent. * 20 Very sick; hospital admission necessary; active supportive treatment necessary. * 10 Moribund; fatal processes progressing rapidly. * 0 Dead
Time frame: Through study completion, an average of 1 year
Physical performance assessed by the Timed-Up-and-Go-Test (TUG)
Timed-Up-and-Go-Test in seconds
Time frame: Through study completion, an average of 1 year
Plan to share: Yes — All collected IPD
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: February 2025 until expiration of collaboration (max. 10 years)
Access criteria: All facilities contributing to the Swiss-STR get access the IPD after request to a review board
Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luzerner Kantonsspital